Table 1 Demographics, clinical characteristics, and treatment regimens of patients with GC/GEJC/EAC
Characteristic | Total | France | Germany | UK | US | Japan | China |
|---|---|---|---|---|---|---|---|
n = 995 | n = 203 | n = 200 | n = 204 | n = 143 | n = 45 | n = 200 | |
Age, years | |||||||
 Mean (SD) | 65.0 (10.3) | 65.0 (9.7) | 65.0 (9.5) | 67.7 (9.7) | 67.9 (9.2) | 70.2 (8.6) | 59.0 (10.9) |
 Median (IQR) | 66.0 (59–72) | 67.0 (60–71) | 65.0 (58–71) | 68.5 (64–74) | 68.0 (61–73) | 70.0 (64–78) | 60.0 (51–67) |
Male, n (%) | 691 (69.5) | 150 (73.9) | 146 (73.0) | 132 (64.7) | 104 (72.7) | 28 (62.2) | 131 (65.5) |
Female, n (%) | 304 (30.5) | 53 (26.1) | 54 (27.0) | 72 (35.3) | 39 (27.3) | 17 (37.8) | 69 (34.5) |
Confirmed diagnosis, n (%) | 995 | 203 | 200 | 204 | 143 | 45 | 200 |
 GC | 610 (61.3) | 130 (64.0) | 121 (60.5) | 100 (49.0) | 57 (39.9) | 31 (68.9) | 171 (85.5) |
 GEJC | 268 (26.9) | 54 (26.7) | 59 (29.5) | 64 (31.4) | 56 (39.2) | 8 (17.8) | 27 (13.5) |
 EAC | 117 (11.8) | 19 (9.4) | 20 (10.0) | 40 (19.6) | 30 (21.0) | 6 (13.3) | 2 (1.0) |
Lauren classification, n (%) | 873 | 181 | 195 | 170 | 100 | 39 | 188 |
 Diffuse | 340 (39.0) | 68 (37.6) | 72 (36.9) | 75 (44.1) | 38 (38.0) | 19 (48.7) | 68 (36.2) |
 Intestinal | 375 (43.0) | 89 (49.2) | 85 (43.6) | 61 (35.9) | 38 (38.0) | 18 (46.3) | 84 (44.7) |
 Mixed | 158 (18.1) | 24 (13.3) | 38 (19.5) | 34 (20.0) | 24 (24.0) | 2 (5.1) | 36 (19.2) |
HER2 status, n (%) | 995 | 203 | 200 | 204 | 143 | 45 | 200 |
 HER2 positive | 210 (21.1) | 30 (14.8) | 42 (21.0) | 27 (13.2) | 20 (14.0) | 5 (11.1) | 86 (43.0) |
 HER2 status negative or unknown | 785 (78.9) | 173 (85.2) | 158 (79.0) | 177 (86.8) | 123 (86.0) | 40 (88.9) | 114 (57.0) |
Current therapy, n (%) | 995 | 203 | 200 | 204 | 143 | 45 | 200 |
 Active first-line systemic therapy | 870 (87.4) | 198 (98.0) | 183 (91.5) | 172 (84.3) | 118 (82.5) | 41 (91.1) | 158 (79.0) |
 Best Supportive Care only | 125 (12.6) | 5 (2.5) | 17 (8.5) | 32 (15.7) | 25 (17.5) | 4 (8.9) | 42 (21.0) |
Current active treatment regimen, n (%) | 870 | 198 | 183 | 172 | 118 | 41 | 158 |
 Anti-angiogenic based | 28 (3.2) | 0 (0.0) | 14 (7.7) | 0 (0.0) | 4 (3.4) | 2 (4.9) | 8 (5.1) |
 Mono chemotherapy | 42 (4.8) | 6 (3.0) | 1 (0.6) | 5 (2.9) | 9 (7.6) | 12 (29.3) | 9 (5.7) |
 Dual chemotherapy | 383 (44.0) | 111 (56.1) | 51 (27.9) | 67 (39.0) | 59 (50.0) | 21 (51.2) | 74 (46.8) |
 Triple chemotherapy | 254 (29.2) | 49 (24.8) | 84 (45.9) | 75 (43.6) | 17 (14.4) | 1 (2.4) | 28 (17.7) |
 Anti-HER2 based | 134 (15.4) | 31 (15.7) | 33 (18.0) | 25 (14.5) | 10 (8.5) | 3 (7.3) | 32 (20.3) |
 Anti-PD1 IO | 29 (3.3) | 1 (0.5) | 0 (0.0) | 0 (0.0) | 19 (16.1) | 2 (4.9) | 7 (4.4) |